Publications by authors named "Stephen Blakemore"

Claim this Profile
D
Discovery of Kinesin KIF18A Inhibitor ATX020: Tactical Application of Silicon Atom Replacement.
Brian A Sparling, Hyelee Lee, Mary-Margaret Zablocki, Maureen M Lynes, Simina Grigoriu, Stephen J Blakemore

ACS Med Chem Lett· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitor.
Gordon J Lockbaum, Maureen M Lynes, Sophie A Shen, Julie Liu, Nicholas Holt, Stephen J Blakemore

Commun Biol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair.
Jennifer Castro, Matthew H Daniels, David Brennan, Brian Johnston, Deepali Gotur, Stephen J Blakemore

Cancer Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BT7480, a novel fully synthetic tumor-targeted immune cell agonist™ ( TICA™) induces tumor localized CD137 agonism.
Kristen Hurov, Johanna Lahdenranta, Punit Upadhyaya, Eric Haines, Heather Cohen, Stephen Blakemore

J Immunother Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Eytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, Raoul Tibes, Jesus G Berdeja, Stephen J Blakemore

Blood· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Antoine Italiano, Jean-Charles Soria, Maud Toulmonde, Jean-Marie Michot, Carlo Lucchesi, Stephen J Blakemore

Lancet Oncol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in -Rearranged Leukemia.
Carly T Campbell, Jessica N Haladyna, David A Drubin, Ty M Thomson, Michael J Maria, Stephen J Blakemore

Mol Cancer Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Kit Man Wong, Lindsey N Micel, Heather M Selby, Aik Choon Tan, Todd M Pitts, Stephen J Blakemore

Invest New Drugs· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.
Ronan T Swords, Harry P Erba, Daniel J DeAngelo, Dale L Bixby, Jessica K Altman, Stephen J Blakemore

Br J Haematol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
George Mulligan, David I Lichter, Alessandra Di Bacco, Stephen J Blakemore, Allison Berger

Blood· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.
Steffan T Nawrocki, Kevin R Kelly, Peter G Smith, Claudia M Espitia, Anthony Possemato, Stephen Blakemore

Clin Cancer Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.
Rakesh Kumar, Stephen J Blakemore, Catherine E Ellis, Emanuel F Petricoin, Dexter Pratt

BMC Genomics· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential gene expression in coronary arteries from patients presenting with ischemic heart disease: further evidence for the inflammatory basis of atherosclerosis.
Gemma Satterthwaite, Sheila E Francis, Kim Suvarna, Stephen Blakemore, Chantelle Ward

Am Heart J· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis